The big boys who would be taking positions do not care one bit about the stock price, they are all about the market cap
I believe we are still a ways off from the intrinsic value of SPL.
Once Vivagel is licensed, with a niiiice upfront payment, SPL will have more cash in the bank to "expedite" the DEP program.
A market cap of $1bn (and thus entry into the ASX200 - actually probably sometime before we hit a market cap of $1bn) isn't too out of the picture with:
1) Vivagel licensed globally - big upfront
2) TGA Approval of Vivagel
3) Topline results of Dep-Dox and commencement of Phase 2
4) Commencement of Phase 1 Dep-Cab
5) One of the dep-conjugate undisclosed partnerships turning into a license - additional upfront
6) Extra AZ deal converting to license - additional upfront
7) AZ moving their first molecule into the clinic - payment
The best part? A market cap of $1bn is approximately $2.71
We will naturally take breathers on the way up with some red days, and itll bob around here and there
But the overall trend is up. Lets gooooo
SPL Price at posting:
$1.04 Sentiment: Hold Disclosure: Held
